

DAFTAR PUSTAKA

- Aditama TY. 2012. Laporan perkembangan situasi HIV& AIDS diIndonesia. Kementerian Kesehatan Republik Indonesia-Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Jakarta. <http://www.depkes.go.id/index.php/component/content/article/43-newsslider/2186-perkembangan-hiv-aids-di-indonesia-triwulan-iii-tahun-2012.html>. Diunduh Kamis 13 Juni 2013.
- Adkinson NF dan Pongracic. 2001Drug Allergy. Dalam: Halgate ST., Chufch MK., Liuchtenstein Im.(eds). *Allergy*. 2nd ed. Mosby. Totonto. Pp. 155-62.
- Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK & Pirmohamed M. 2006. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. *Pharmacogenomics*7(6): 813-8.
- Alomar MJ. 2014. Factors affecting the development of adverse drugreactions (Review article). *Saudi Pharmaceutical Journal* (2014) 22, 83–94.
- Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, Phanuphak P, Ruxrungtham K, lange J, Cooper DA. 2005 Incidence and risk factors for exantema in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. *AIDS* jan 28;19(2):185-92
- Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di Giambenedetto S, Barracchini A, De Longis P, Murri R, Tozzi V, Ammassari A, Rizzo MG, Ippolito G, De Luca A. 2001Female sex and the use of anti-allergic agents increase the risk of developing cutaneous exantema associated with nevirapine therapy. *AIDS*15:1579-81.
- Archbold JK, Macdonald WA, Gras S, Ely LK, Miles JJ, Bell MJ, Brennan RM, Beddoe T, Wilce MCJ, Clements CS, Purcell AW, McCluskey J, Burrows SR, and Rossjohn J. 2009 Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. *J Exp Med*.19; 206(1): 209-19.
- Bartlett J. 2001. Severe liver toxicity in patients receivingtwo nucleoside analogues and a nonnucleosidereverse transcriptase inhibitor. 8th *Conference on Retroviruses and Opportunistic Infections*.Chicago, IL.
- Baum H, Butler P, Davies H, Sternberg MJE, Burroughs AK. 1993. Autoimmune diseases and molecular mimicry: a hypothesis. *Trends Biochem Sci* 4:140-4.
- Bayoumi AM, Barnett PG, Joyce VR,.Griffin SC, Sun H, Bansback SJ, Holodniy M, Sanders G, Brown ST, Kyriakides TC, Angus B, Cameron DW, Anis AH, Sculpher M, Owens DK.2013. Cost-effectiveness of newer antiretroviral drugs in treatment-experiencedpatients with multidrug-resistant HIV disease. *J Acquir Immune Defic Syndr*. 64(4):382-391.
- Beer L, Heffelfinger J, Frazier E, Mattson C, Roter B, Barash E, Buskin S, Rime T and Valverde E. 2012. Use of and Adherence to Antiretroviral Therapy in a Large U.S. Sample of HIV-infected Adults in Care, 2007-2008. *The Open AIDS Journal, Volume 6 (Suppl 1: M21) 213-23*.

- Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick HJ Jr, Powderly WG, Mundy LM. 2001 Sex differences in nevirapine exantema. *Clin Infect Dis* 32:124-9.
- Bharadwaj M, Illing P, Kostenko L. 2010 Personalized Medicine for HLA-associated Drug-hypersensitivity Reactions. *Personalized Medicine*. 7(5):495-516.
- Bissell D, Gores G, Laskin D, Hoofnagle J. 2001 Drug-induced liver injury: mechanisms and test systems. *Hepatology* 33:1009-13.
- Boediardja ST, Moeslichan S, Cornain S, Budimulya U, Djuanda A. 2000. Med J Indones. 9 (4): 223-31.
- Bosque A and Planelles V. 2009 Induction of HIV-1 latency and reactivation in primary memory CD4⁺ T cells. *Blood* 113:58-65.
- Britschgi M, von Greyer S., Burkhart C., Pichler WJ. 2003 Molecular Aspect of Drug Recognition by Specific T Cells. *Current Drug Targets* 4: 1-11.
- Carr A, Cooper DA. 2000. Adverse effects of antiretroviral therapy. *Lancet* 356:1423-30.
- Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. 1999 Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. *Lancet* 353:2093-9.
- Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ. 1999 HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. *Science*, 283:1748-52.
- Carrington M, O'Brien SJ. 2003. The influence of HLA genotype on AIDS. *Annu Rev Med*; 54:535-51.
- Chan DJ, Ray JE, McNally L, Batterham M and Don E. Smith. 2008. Correlation Between HIV-1 RNA Load in Blood and Seminal Plasma Depending on Antiretroviral Treatment Status, Regimen and Penetration of Semen by Antiretroviral Drugs. *Curr HIV Res* 6: 477-84.
- Chantarangsu S. 2009. Pharmacogenomics and its application. http://www.thaitox.org/media/upload/file/NCT2nd/pharmacogenomics_NCT_2009.pdf. Diunduh Jumat 28 Desember 2012.
- Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y. 2009. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. *Pharmacogenet Genomics* 9:139-146.
- Chaponda M, Pirmohamed M. 2010. Hypersensitivity reactions to HIV therapy. *Br J Clin Pharmacol* 71(5):659-671.
- Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ. 1993. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. *Antimicrob Agents Chemother*. 37:178-82.
- Chen J, Mannargudi BM, Xu L, Uetrecht J. Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. *Chem Res Toxicol*. 2008 Sep;21(9):1862-70. doi: 10.1021/tx800177k. Epub 2008 Aug 26.

- Chen LF, Hoy J and Lewin SR. 2007 Ten years of highly active antiretroviral therapy for HIV infection. *Med J Aust* 186 (3): 146-51.
- Chudasama AS, Patel VV, Nivsarkar M, Vasu KK, and Shishoo CJ. 2014. *In vivo* Evaluation of Self Emulsifying Drug Delivery System for Oral Delivery of Nevirapine. *Indian J Pharm Sci*. May-Jun; 76(3): 218-24.
- Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE; AIDS Clinical Trials Group 383 Study Team. 2002 Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. *AIDS* 16:1915-23.
- Chung WH, Hung SI, Hong HS, Hsieh MS, Yang LC, Ho HC, Wu JY, Chen YT. 2004. Medical genetics: a marker for Stevens-Johnson Syndrome. *Nature* 428 (6982): 486.
- Claes P, Wintzen M, Allard S, Simons P, De Coninck A, Lacor P. 2004. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine. *Eur J Int Med* 15:255-8.
- Clark RA., Chong B., Mirchandani N., Brinster NK., Yamanaka K., Dowgiert RK. and Kupper TS. 2006 The Vast Majority of CLA+ T Cells Are Resident in Normal Skin. *Immunol* 176: 4431-39.
- Claudio GA, Marfin AF, de Dios Perrino S, Velasco AA. 2001. DRESS syndrome associated with nevirapine therapy. *Arch Intern Med* 161:2501-2.
- Coffey S. 2001. Nevirapine (Viramune). <http://hivinsite.ucsf.edu/InSite?page=ar-02-01> Diunduh Jumat 28 Desember 2012.
- Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. 2008 The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. *J Clin Invest* 118 (4): 1244-54.
- Cooper CL, van Heeswijk RPG. 2007 Reviews in Antiretroviral Therapy: Once-daily Nevirapine Dosing: Clinical Pharmacology of Nevirapine. *HIV Medicine* 8(1):1-7.
- Cressey TR., Lallement M. 2007 Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. *Infect Genet Evol.* 7:333-42.
- Crowson AN, Magro C. 2001. The cutaneous pathology of lupus erythematosus: a review. *J Cutan Pathol* 28: 1-23.
- Dailly E, Billaud E, Reliquet V, Breurec S, Perre P, Le'autez S, Jolliet P, Bourin M, Raffi F. 2004 No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. *Eur J Clin Pharmacol* 60: 343-8.
- Davis CM and Shearer WT. 2008 Diagnosis and management of HIV drug hypersensitivity. *J Allergy Clin Immunol* 121(4):826-32.
- de Maat MM, Nellen JF, Huitema AD, Wit FW, Mulder JW, Prins JM, Beijnen JH. 2004 Race is not associated with nevirapine pharmacokinetics. *Ther Drug Monit* 26: 456-8.

- de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, van Gorp EC, Huitema AD, Beijnen JH. 2003 Incidence and risk factors for nevirapine-associated rash. *Eur J Clin Pharmacol*. Sep;59(5-6):457-62.
- Demoly P and Bousquet J. 2001. Epidemiology of drug allergy. *Curr Opin Allergy Clin Immunol* 1:305-310.
- Demoly P, Gomes ER. 2005. Drug hypersensitivities: definition, epidemiology and risk factors. *Allerg Immunol* 37: 202-6.
- Depkes RI (2009). Profil Kesehatan Indonesia. Jakarta: Departemen Republik Indonesia.
- De Requena DG, Jimenez-Nacher I, Soriano V. 2005 Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. *AIDS Res Hum Retroviruses* 21:555-9.
- Dhaliwal JS, Shahnaz M, Too CL, Azrena A, Maiselamah L, Lee YY, Irda YA, salawati M. 2007. HLA-A, -B and -DR Allele and Haplotype frequencies in Malays. *Asian Pacific Journal of Allergy and Immunology* 25:47-51.
- Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M, Koup RA. 2002. HIV preferentially infects HIV-specific CD41 T cells. *Nature*. 417:95-8.
- Douek DC, Roederer M, and Koup RA. 2009 Emerging Concepts in the Immunopathogenesis of AIDS. *Annu Rev Med*. 60: 471-84.
- Dunn PPJ. 2011 Human leucocyte antigen typing: techniques and technology, a critical appraisal. *Int J Immunogenet*. Dec;38(6):463-73.
- Eliasiewicz M, Flahault A, Roujeau JC, Fillet AM, Challine D, Mansouri S, Wolkenstein P, Aractingi S, Assathiany DP, Maslo C, Villada IB, Chosidow O. Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. *JAAD*. 47 (1):40-6.
- Ernst FR, Grizzle AJ. 2001 Drug-related morbidity and mortality: updating the cost-of-illness model. *J Am Pharm Assoc (Wash)*. Mar-Apr;41(2):192-9.
- Fellay J, Kevin V, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Antonella Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, and Goldstein DB. 2007. A whole-genome association study of major determinants for host control of HIV-1. *Science*. 317:944-7.
- Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB, Yee HF Jr, Martin JN, Deeks SG, Shacklett BL. 2009 Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. *Blood*. 113:3978-89.
- Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, and The AZT Collaborative Working Group. 1987. The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. *N Engl J Med*. 317:185-191.
- Flexner C. 1998. HIV-Protease inhibitors. *NEJM*. 338(18):1281-93.

- Foley B, Donegan E, Silitonga N, Wignall FS, Busch MP, Delwart EL. 2001. Importation of multiple HIV type 1 strains into West Papua, Indonesia (Irian Jaya). *AIDS Res Hum Retroviruses*. 20;17(17):1655-9.
- Fuger L. 1994. PCR and RFLP studies of inherited susceptibility to autoimmune disorders, with special reference to multiplesclerosis. *Dan Med Bull* 1994; Vol 11: 38-49.
- Fujinami RS, von Herrath MG, Christen U, Whitton JL. 2006. Molecular Mimicry, Bystander Activation, or Viral Persistence: Infections and Autoimmune Disease. *Clin. Microbiol. Rev.* 19(1):80-94.
- Gaffar A. 2006. Hypersensitivity reactions. Dalam Male D, Brostoff J, Roth D and Roitt I. *Immunology*. 7th Edition pp.23-26., New York, Mosby, Elsevier
- Gangar M, Arias G, O'Brian JG, Kemper CA. 2000 Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. *Ann Pharmacother*. 34:839-42.
- Gao X. 1992. Allele frequencies in worldwide populations. *Human Immunol*, 34,153. http://www.allelefreqencies.net/pop6001c.asp?pop_name=Indonesia%20Java%20Yogyakarta%20Region. Diunduh Senin 25 Juli 2006.
- Gao S, Gui X, Liang K, Liu Z, Hu J and Dong B. 2012. HLA-Dependent Hypersensitivity Reaction to Nevirapine in Chinese Han HIV-Infected Patients. *AIDS Research and Human Retroviruses* 28(6):540-3.
- Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, Tachikawa N, Kikuchi Y, Oka S. 2007. HLA-Cw8 primarily associated with hypersensitivity tonevirapine. *AIDS* 21:264–265.
- Gavazzi G, Bouchard O, Leclercq P, Morel-Baccard C, Bosseray A, Dutertre N, Micoud M, Morand P. 2000. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? *AIDS Res Hum Retroviruses*. 16:1021–23.
- Granados DP, Sriranganadane D, Daouda T, Zieger A, Laumont CM, Caron-Lizotte O, `ve Boucher G, Hardy MP, Gendron P, Co`te` C, Lemieux S, Thibault P & Perreault C. 2014. Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. *Nature Communications* 5:3600. 1-14.
- Guengerich FP. 2006. Cytochrome P450s and Other Enzymes in Drug Metabolism and Toxicity. *The AAPS Journal* 8(1):E101-11.
- UIf Gyllensten U and Allen M. 1991. PCR-based HLAClass II Typing. *Genome Res*. 1: 91-8.
- Hargrave KD, Proudfoot JR, Grozinger KG, Cullen E, Kapadia SR, Patel UR, Fuchs VU, Mauldin SC, Vitous J, Behnke ML. 1991. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. *JMed Chem*. 34(7):2231–41.
- Harris M, Zala C, Hogg R, Montaner JSG. 2008. Nevirapine. In. Dolin R, Masur H, Saag M (eds). *AIDS Therapy*. 3rd ed. Churchill Livingstone, Philadelphia, 233-45.

- Hausmann O, Schnyder B, Pichler WJ. 2010. Drug Hypersensitivity Reactions Involving Skin. Dalam Uetrecht J.(ed). *Adverse Drug Reactions. Handbook of Experimental Pharmacology*. Springer, New York. Pp 29-55.
- Havlrir D, McLaughlin MM, Reichman DD. 1995. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of $>500/\text{mm}^3$: AIDS Clinical Group Protocol 208. *J Infect Dis*. 172: 1379-83.
- Heinemann FM. 2009. HLA Genotyping and Antibody Characterization Using the Luminex™ Multiplex Technology. *Transfus Med Hemother*. 36(4): 273–27.
- Homolya L, Váradi A, Sarkadi B. 2003. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. *Biofactors*. 17 (1-4): 103–14.
- Horton R, Wilming L, Rand V. 2004. Gene map of the extended human MHC. *Nat. Rev. Genet*. 5(12):889-99.
- Hülsmeier M, Fiorillo MT, Bettosini F, Sorrentino R, Saenger W, Ziegler A, Uchanska-Ziegler B. 2004. Dual HLA-B27 subtype-dependent conformation of a self-peptide. *J. Exp. Med*. (2): 271-81.
- Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT. 2006. Genetic Susceptibility to carbamazepine-induced cutaneous adverse drug reactions. *Pharmacogenet. Genomics* 16(4): 297-306.
- Hosein SR, Ziegler B. 2014. Nevirapine-Viramune. <http://www.catie.ca/fact-sheets/non-nukes/nevirapine-viramune>. Diunduh Senin 25 Juli 2016
- Infodatin. 2014. <http://www.depkes.go.id/resources/download/pusdatin/infodatin/Infodatin%20AIDS.pdf>
- Itoh Y, Mizuki N, Shimada T, Azuma F, Itakura M, Kashiwase K, Kikkawa E, Kulski JK, Satake M, Inoko H. 2005. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR–SSOP–Luminex method in the Japanese population. *Immunogenetics*. 57: 717-29.
- Janeway CA, Jr, Travers P, Walport M and Shlomchik MJ. 2001. *Immunobiology: The Immune System in Health and Disease*. 5th edition. New York: Garland Science.
- Janmonhamed A, Dolphin CT, Phillips IR, Shephard EA. 2001. Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochrom P450. *Biochem Pharmacol*. 62: 777-786
- Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. 2003. CD41 T cells are required for secondary expansion and memory in CD81 T lymphocytes. *Nature*. 421:852–6.
- Jeannet M, Sztajzel R, Carpentier N, Hirschel B, Tiercy JM. 1989. HLA antigens are risk factors for development of AIDS. *J Acquir Immune Defic Syndr*. 2:28–32.
- Jin P and Wang E. 2003. Polymorphism in clinical immunology – From HLA typing to immunogenetic profiling. *J Translational Med*. 1(8):1-11.

- Jin X, Gao X, Ramanathan Jr M, Deschenes GR, Nelson GW, O'Brien SJ, Goedert JJ, Ho DD, O'Brien TR and Carrington M. 2002. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. *J Virol*; 76:12603–10.
- John M, Flexman J, French A. 1998. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? *AIDS*. 12:2289-93.
- Joy S, Poi M, Hughes L, Brady MT, Koletar SL, Para MF, Fan-Havard P. 2005 Third-trimester maternal toxicity with nevirapine use in pregnancy. *Obstet Gynecol*. 106(5 Pt 1):1032-8.
- Julg B, Moodley ES, Qi Y, Ramduth D, Reddy S, Mncube Z, Gao X, Goulder PJ, Detels R, Ndung'u T, Walker BD, Carrington M. 2011. Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. *J Infect Dis*. Mar 15; 203(6):803-9
- Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, Beijnen JH; 2NN Study Group. 2005. A Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. *HIV Clin Trials*6: 254–61.
- Kappelhoff BS, Van Leth F, Robinson PA, mac Gregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD. 2005b. Are adverse events of nevirapine and efavirenz related to plasma concentrations? *Antivir Ther*. 10(4):489-98.
- Keller M., Spanou Z., Schaerli P., Britschgi M., Yawalkar N., Seitz M., Villiger PM., Pichler WJ. 2005. T Cell-Regulated Neutrophilic Inflammation in Autoinflammatory Diseases1. *J Immunol*. 175: 7678-86.
- Kemenkes RI. 2011. *Pedoman Nasional Tata laksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa*. Kementerian kesehatan Republik Indonesia- Direktorat Jenderal Pengendalian Penyakit dan penyehatan Lingkungan. Jakarta
- Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F. 2009. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. *Pharmacoepidemiol Drug Saf*. Sep; 18(9):848-57.
- Khan FD, Roychowdhury S, Gaspari AA, Svensson CK. 2006. Immune response to xenobiotics in the skin: from contact sensitivity to drug allergy. *Expert Opin Drug Metab Toxicol*. Apr; 2(2): 261-72.
- Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S, Sura T, Chantratita W. 2008. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. *Curr HIV Res*. Jan; 6(1):65-9.
- Kilmarx PH, Kretsinger K, Millet GA. 2009. Considerations in the role of male circumcision in the prevention of HIV transmission in the United States. *Future HIV Ther* 3(3):241-54.
- Kimber I. and Cumberbatch M. 1992. Dendritic Cells and Cutaneous Immune Responses to Chemical Allergens. *Toxicol Appl Pharmacol* 117: 137-146.

- Kimia Farma. 2012. Rincian produk. http://www.kimiafarma.co.id/?page=product_detail&cat=4&subcat=409&prod=169. Diunduh Sabtu, 5 Januari 2003.
- Knowles SR, Shapiro LE, Shear NH. 1999. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. *Drug Saf. Dec*; 21(6): 489-501.
- Komisi Penanggulangan AIDS Nasional (KPAN). 2007 Laporan KPA Nasional. 2007. <http://www.aidsindonesia.or.id/repo/laporanKPANasional2007.pdf>. Diunduh 8 Agustus 2008.
- KPAD Yogyakarta, 2014. <http://aidsyogya.or.id/category/data-hiv-aids/>
- Kroon LA. 2007. Drug interactions with smoking. *Am J Health-Syst Pharm*; 64:1917-21.
- Kumar V, Abbas AK, Fausto N. Robbins and Cotra. 2005. Pathologic basis of disease, Volume 1. Elsevier Saunders.
- Lacap PA, Huntington JD, Luo M, Nagelkerke NJ, Bielawny T, Kimani J, Wachih C, Ngugi EN, Plummer FA. 2008. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. *AIDS*; 22:1029–38.
- Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatucci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. *N Engl J Med*. 348(22):2175-85.
- Launay O, Roudiere L, Boukli N, Dupont B, PrevotEAU du Clary F, Patey O, David F, Lortholary O, devidas A, Piketty C, Rey E, Urbinelli R, Allaert FA, Treluyer JM, Kiertiburanakul S, Malathum K, Watcharananan S, Sathapatayayongs B, Sungkanuparph S. 2009. Predicting factors for unseccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin exantema. *Int J STD AIDS Mar*;20(3):176-9.
- Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*. Apr 15; 279(15):1200-5.
- Leist M, Gantner F, Kunstle G, Wendel A. 1998. Cytokine-mediated hepatic apoptosis. *Rev Physiol Biochem Pharmacol*133:109–55.
- Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Tunthanathip P, Nakayama EE, Shioda T. 2009. HLA-Cw*04 allele associated with nevirapine-induced exantema in HIV-infected Thai patients. *AIDS Res Ther*.9 Oct 21; 6:22.
- Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Casula B, La Nasa G, Manconi PE. 2006. HLA-dependent hypersensitivity to neverapine in Sardinian HIV patients. *AIDS* 1; 20(12):1621-6.
- Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC; RegiSCAR Group. 2006. A marker for Stevens-Johnson syndrome ...: ethnicity matters. *Pharmacogenomics J*.6(4):265-8.

- Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. 2005. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. *AIDS* 19: 63-7.
- Malhotra U, Holte S, Dutta S, Berrey MM, Delpit E, Koelle DM, Sette A, Corey L, McElrath MJ. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. *J Clin Invest*; 107:505-17.
- Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, and Gunther S. 2001. Reactivation of Hepatitis B Virus Replication Accompanied by Acute Hepatitis in Patients Receiving Highly Active Antiretroviral Therapy. *CID*. 32: 144-8.
- Mann DL, Murray C, Yarchoan R, Blattner WA, Goedert JJ. 1988. HLA antigen frequencies in HIV-1 seropositive disease-free individuals and patients with AIDS. *J Acquir Immune Defic Syndr*. 1:13-7.
- Manosuthi W, Sungkanuparph S, tansuphaswadikul S, Inthong Y, Prasithsirikul W, Chottanapund S, mankatitham W, Chimsuntorn S, Sittibusay C, Moolasart V, Chumpathat N, Termvises P, and Chaovavanich A. 2007. Incidence and risk factors of nevirapine associated skin rashes among HIV-infected patients with CD4 cell counts < 250 cells/uL. *Int J STD AIDS* 18:782-786.
- Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S. 2005. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. *AIDS*. 3;19(1):97-9.
- Massimo P, Carlo T, Diego R, Francesco C, Serena Z, Barbara Z, Angiola S, Valeria P, Salvatore C, Lina T, Eugenia QR, Maurizio F, Luisa B, Piergiovanni G, Francesco C, Giampiero C. 2003. Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome. *JAIDS* 32: 259-67.
- Masson MJ, Collins LA, Pohl LR. 2010. The Role of Cytokines in the Mechanism of Adverse Drug Reactions. Dalam. Uetrecht J.(ed). *Adverse Drug Reactions. Handbook of Experimental Pharmacology*. Springer, New York. Pp.195-232.
- Mastroianni CM, Trinchieri V, Santopadre P, Lichtner M, Forcina G, D'Agostino C, Corpolongo A, Vullo V. 1998. Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. *AIDS*. 12:1939-40.
- Max B, Sherer R. 2000. Management of the adverse effects of anti retroviral therapy and medication adherence. *CID*. 30 (suppl 2): S96-116.
- Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. 2002. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor induced rash. *AIDS*. 16:1566-1568.
- McKenna JK, Leiferman KM. 2004. Dermatologic drug reactions. *Immunol Allergy Clin North Am*. 24: 399-423.
- McNicholl I. 2007. Adverse Effect of Antiretroviral Drugs. Diakses dari <http://hivinsite.ucsf.info>. Diunduh tanggal 8 April 2010.
- Meng X, Howarth A, Earnshaw CJ, Jenkins RE, French NS, Back DJ, Naisbitt DJ, Park BK. 2013. Detection of drug bioactivation in vivo: mechanism of

- nevirapine-albumin conjugate formation in patients. *Chem Res Toxicol.* Apr 15; 26(4):575-83.
- Merati TP, Ryan CE, Spelman T, Wirawan DN, Bakta IM, Otto B, Oelrichs RB, Crowe SM. 2011. CRF01_AE dominates the HIV-1 epidemic in Indonesia. *Sexual Health.* 9(5):414-421.
- Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. *Science.* 250:1411-3.
- Mesquita F, Winarso I, Atmosukarto II, Eka B, Nevendorff L, Rahmah A, Handoyo P, Anastasia P, Angela Rc. 2007. Public health the leading force of the Indonesian respons to HIV/AIDS crisis among people who inject drugs. *Harm Reduct J.* 4:9.
- Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. 1998. Pharmacokinetics of nevirapine in human immunodeficiency virus type-1 infected pregnant women and their nenates. Pediatric AIDS Clinical trils Group Protocol 250 Team. *J. Infect. Dis.* 178: 368-74.
- Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM. 1998. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. *JAMA;* 279:930–7.
- Munir D. 2006. Peran HLA pada Karsinoma Nasofaring. Suplemen Majalah Kedokteran Nusantara 324 Volume 39 No. 3: 324-30.
- NaisbittDJ. 2004. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. *Toxicol.* 194(3):179-96.
- Nasronudin. 2007. HIV & AIDS. Pendekatan Biologi Molekuler, Klinis dan Sosial. Surabaya: Airlangga University Press.
- Nunez M. 2006. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. *J Hepatol.* 44:S132-S139.
- Nur Rahmi Hidayati NR, Abdillah S, Keban SA. 2016. The analysis of adverse drug reaction in patients with HIV/AIDS who used anti retroviral therapy in RSUDGunung Jati Cirebon period 2013. *Pharmaciana.* Vol. 6, No. 1; 2:79-88
- Ototokun I, Pomeroy C. 2003. Sex differences inadverse reactions to antiretroviral drugs. *Top HIVMed.* 11:55-59.
- PantaleoG andFauciAS. 1995. New Concepts in the Immunopathogenesis of HIV Infection. *Ann. Rev. Immunol.* 13:487-512.
- Peterson P, Gekker F, Hu S, and Chao CC. 1994. Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures. *Antimicrob Agents Chemother.* 38:2465-8.
- Phillips EJ & Mallal SA. 2010. Pharmacogenetics of drug hypersensitivity. *Pharmacogenomics.* 11(7):973-987.
- Pichler WJ. 2003. Delayed drug hypersensitivity reactions. *Ann Intern Med.* Oct 21; 139(8): 683-93.

- Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, Kuechler P, Naisbitt D. 2002. Cellular and molecular pathophysiology of cutaneous drug reactions. *Am J Clin Dermatol*. 3(4):229-38.
- Pichler W, Yawalkar N, Schmid S, Helbling A. 2002. Pathogenesis of drug-induced exanthems. *Allergy*. 57 (10): 884-93.
- Pirmohamed M. 2006. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. *The AAPS Journal*. 8(1):E20-E26.
- Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. 2002. The danger hypothesis-potential role in idiosyncratic drug reactions. *Toxicol*. 181 (182):55-63.
- Posadas, S. J. and Pichler, W. J. 2007. Delayed drug hypersensitivity reactions – new concepts. *Clin Exp Allergy*; 37: 989–99.
- Pudjiati SR. 2011. Mucocutaneous manifestations in HIV-infected Indonesian patients. *Neth.J.Der-Ven March*. (Suppl).
- Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. 2002. Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. *Proc Natl Acad Sci USA* 99 (22): 14410–5.
- Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, Svensson CK. 2000. A Role for Bioactivation and Covalent Binding within Epidermal Keratinocytes in Sulfonamide-Induced Cutaneous Drug Reactions. *J Invest Dermatol*. 114:1164-1173.
- Riedl MA and Casilla AM. 2003. Adverse drug reactions: types and treatment options. *Am Fam Physician*. Nov 1; 68(9): 1781-91
- Riley RJ, Leeder JS. 1995. *In vitro* analysis of metabolic predisposition to drug hypersensitivity reactions. *Clin Exp Immunol*. 99:1-6.
- Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J. 1999. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. *Drug Metab Dispos*. 8:895– 901.
- Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. 1998. Hepatotoxicity after introduction of highly active antiretroviral therapy. *AIDS*. 12:1256.
- Roselinda dan Jekti RP. 2012. Genotype and transmission Human Immunodeficiency Virus-1 in seven provinces in Indonesia. *Health Science Indones*. 3; 2:27-31.
- Roujeau JC. 2006. Immune Mechanisms in Drug Allergy. *Allergol Int*. 55: 27-33.
- Roychowdhury S, Svensson CK. 2005. Mechanisms of Drug-induced Delayed-type Hypersensitivity Reactions in the Skin. *AAPS Journal*. 7(4): E834-E846.
- Rutschmann O, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin L. 1998. Impact of treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfecting with HIV. *J Infect Dis*. 177:783-5.
- Salam N, Rane S, Das R, Faulkner M, Gund R, Kandpal U, Lewis V, Mattoo H, Prabhu S, Ranganathan V, Durdik J,* George A, Rath S, and Bal V. 2013. T cell ageing: Effects of age on development, survival & function. *Indian J Med Res*. Nov; 138(5): 595–608.
- Sanderson JP., Naisbitt DJ. and Park BK. 2006. Role of Bioactivation in Drug-Induced Hypersensitivity Reactions. *The AAPS Journal*; 8(1) Article 7:E55-E64

- Scheller S. 2011. Symptoms and phases of HIV infection & Aids. HYPERLINK http://www.health.am/aids/more/symptoms_and_phases_of_hiv_infection_aids/#ixzz2AYPOXjsL. Diunduh Sabtu 29 Desember 2012.
- Schuetz EG, Furuya KN, Schuetz JD. 1995. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. *J Pharmacol Exp Ther*. 275:1011-1018.
- Severino G and Zompo MD. 2004. Adverse drug reactions: role of pharmacogenomics. *Pharmacol Res*. 49: 363-73.
- Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. *Cold Spring Harb Perspect Med*. Sep;1(1):a006841.
- Shenton JM, Popovic M, Uetrecht JP. 2007. Nevirapine Hypersensitivity. Pichler WJ (ed): *Drug Hypersensitivity*. Basel, Karger, pp 115–28.
- Shepherd GM. 2003. Hypersensitivity reactions to drugs: evaluation and management. *Mt Sinai J Med*. 70: 113-25.
- Shiohara T., Takahashi R., Kano Y. 2007. Drug-Induced Hypersensitivity syndrome and Viral Reactivation. Dalam. Pichler WJ(ed). *Drug Hypersensitivity*. Karger, Basel. 251-266.
- Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach JL, Mitsuya H. 1995. Comparative Analysis of Anti-Human Immunodeficiency Virus Type 1 Activities of Dideoxynucleoside Analogs in Resting and Activated Peripheral Blood Mononuclear Cells. *Antimicrob Agents Chemother*. 39(11): 2555–9.
- Smith PF, DiCenzo R, Morse GD. 2001. Clinical Pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. *Clin. Pharmacokinet*. 40;893-905.
- Soebono H, Giphart MJ, Schreuder GM, Klatser PR, de Vries RR. 1997. Associations between HLA-DRB1 alleles and leprosy in an Indonesian population. *Int J Lepr Other Mycobact Dis*. Jun;65(2):190-6.
- Steiner H, Polliack A, Kimchi-Sarfaty C, Libster D, Fibach E, Rund D. 1998. Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity. *Ann Hematol*. 76:189-194.
- Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; Liverpool TDM Database; UK CHIC Study. 2008. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. *Antivir Ther* 13: 675-85.
- Stone S, Lee S, Keane N, Price P, French M. 2002. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus–HCV coinfecting patients. *J Infect Dis*. 186:1498–502.
- Sun JC, Williams MA, Bevan MJ. 2004. CD41 T cells are required for the maintenance, not programming, of memory CD81 T cells after acute infection. *Nat Immunol*; 5:927–33.
- Subronto YW, Budiarto, Pulungsih SP, Lingga JG, Prameswari HD. 2011. *Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral*

- pada Orang Dewasa*. Kementerian Kesehatan RI - Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Jakarta.
- Swanson HI. 2004. Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective. *Chem Biol Interact*. 149: 69-79
- Tatari Z, Fortier C, Bobrynina V, Loiseau P, Charron D, Raffoux C. 1995. HLA-Cw allele analysis by PCR-restriction fragment length polymorphism: Study of known and additional alleles. *Proc. Natl. Acad. Sci. USA*; 92: 8803-7.
- Taylor CJ, Smith SI, Morgan CH, Stephenson SF, Key T, Srinivasan M, Cunningham E Jr, Watson PG. 2000. HLA and Mooren's ulceration. *Br J Ophthalmol*. 84:72-5.
- Thong B, Motala C, Vervloet D. 2007. Drug allergy. *WAO World Allergy Organization*. http://www.worldallergy.org/professional/allergic_diseases_center/drugallergy/. Diunduh Minggu 30 Desember 2012.
- Toh H, Savoie CJ, Kamikawaji N, Muta S, Sasazuki T, Kuhara S. 2000. Changes at the floor of the peptide-binding groove induce a strong preference for proline at position 3 of the bound peptide: molecular dynamics simulations of HLA-A*0217. *Biopolymers*. 54 (5): 318-27.
- Uetrecht J. 2005. Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivity. *Toxicology*. 209: 113-118.
- Umapathy S, Pawar A, Bajpai S, Pazare AR, and Ghosh K. 2011. HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients. *J Pharmacol Pharmacother*. 2(2): 114-5.
- UNAIDS. 2009. AIDS Epidemic update <http://books.google.co.id/books?hl=en&lr=&id=gPxZFo5QVe8C&oi=fnd&pg=PA1&dq=UNAIDS>. Diunduh Minggu 10 Mei 2013.
- UNAIDS. 2011. US, RI partnership to fight HIV/AIDS continues. HYPERLINK <http://proquest.umi.com.ezproxy.utas.edu.au/pqdlink?Ver=1&Exp=09-13-2015&FMT=7&DID=1916388651&RQT=309>. Diunduh 30 Desember 2012.
- Vandebriel RJ. 2004. Gene polymorphism within the immune system that may underlie drug allergy. *Naunyn Schmiedebergs Arch Pharmacol*. 369(1):125-32.
- van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM. 2000. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. *AIDS*. 14: F77-F82.
- van Leth F, Andrews S, Grinsztejn B. 2005. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. *AIDS*. 19 (5): 463-71.
- Vento S, Garofano T, Renzini C, Casali F, Concia E. 1998. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. *AIDS*. 12:116-7.
- Vitezica ZG, Milpied B, Lonjou C, Borot N, Ledger TN, Lefebvre A, Hovnanian A. 2008. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. *AIDS*. 19;22(4):540-1.
- von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, and Haberl A. 2006. A comparison

- of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. *Br J Clin Pharmacol*. 62: 552–9
- Vyakarnam A, Sidebottom D, Murad S, Underhill JA, Easterbrook PJ, Dalgleish AG, Peakman M. 2004. Possession of human leucocyte antigen DQ6 alleles and the rate of CD4 T-cell decline in human immunodeficiency virus-1 infection. *Immunology*; 112:1
- Warren KJ, Boxwell DE, Kim NY, Drolet BA. 1998 Nevirapine-associated Stevens-Johnson syndrome. Research Letters. *Lancet* Feb 21; 351:567.
- Warrington R and Silviu-Dan F. 2011. Drug allergy. *Allergy, Asthma & Clinical Immunology*, 7(Suppl 1):S10.
- Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH. 1995 Viral dynamics in human immunodeficiency virus type 1 infection. *Nature* 373:117-22.
- Weiss. 2003. How does HIV cause AIDS? *Science*. May 28; 260(5112):1273-9.
- WHO. 2005 Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance. <http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf>. Diunduh Sabtu 6 Januari 2013.
- WHO. 2006. WHO Guidelines on Cotrimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. <http://hivinsite.ucsf.edu/InSite?page=jl-65-02>
- Williams TM. 2001. Human Leukocyte Antigen Gene Polymorphism and the Histocompatibility Laboratory. *JMD* August, Vol. 3, No. 3: 98-104.
- Wong KH, Chan KC, Lee SS. 2001. Sex differences in nevirapine rash. *Clin Infect Dis*. 33:2096-2098.
- Wooltorton E. 2004 Health and Drug Alerts *CMAJ*. 170(7): 1091.
- Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczek D, and Haas DW. 2011. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. *AIDS*. 25(10): 1271–80.
- Yuliwulandari R, Kasiwashe K, Nakajima H, Uddin J, Susmiarsih TP, Sofro ASM, Tokunaga K. 2008. Polymorphisms of HLA genes in Western Javanese (Indonesia): close affinities to Southeast Asian populations. *Tissue antigen*. Vol. 73:46–53.
- Zanni MP, von Greyers S, Hari Y, Schnyder B, Pichle WJ. 1999 Recognition of Local Anesthetic by $\alpha\beta$ + T Cells. *J Invest Dermatol*; 112: 197-204.
- Zhang H, Dornadula G, Wu J, Havlir D, Richman DD, Pomerantz RJ. 1996 Kinetic analysis of intraviral reverse transcriptase in the blood plasma of HIV-1 infected individuals. *J Virol* 70:628-34.
- Zhou X-J, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M, Sommadossi J-P, and The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. 1999 Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients. *Antimicrob Agents Chemother*. 1999. January; 43(1): 121–128.